Recent Advances in Anti-Obesity Agents / 대한내과학회지
Korean Journal of Medicine
; : 501-508, 2018.
Article
en Ko
| WPRIM
| ID: wpr-718868
Biblioteca responsable:
WPRO
ABSTRACT
Obesity is a chronic disorder that is a significant risk factor for diabetes, cardiovascular diseases, malignancy, and other chronic diseases. Lifestyle modifications form the basis of most treatments for obesity, but it has become clear that such modifications alone are not enough for many obese patients. When a behavioral approach is insufficient, pharmacological treatment may be recommended. In recent years, the US Food and Drug Administration (FDA) has withdrawn several therapeutic options for obesity due to their side effects, but has approved four novel anti-obesity agents. Until recently, orlistat was the only drug approved for the management of long-term obesity, but the US FDA approved the novel anti-obesity drugs lorcaserin and phentermine/topiramate in 2012, and naltrexone/bupropion and liraglutide in 2014. The present review discusses the different pharmacotherapeutic options for the treatment of obesity.
Palabras clave
Texto completo:
1
Base de datos:
WPRIM
Asunto principal:
United States Food and Drug Administration
/
Enfermedades Cardiovasculares
/
Enfermedad Crónica
/
Factores de Riesgo
/
Fármacos Antiobesidad
/
Liraglutida
/
Estilo de Vida
/
Obesidad
Tipo de estudio:
Etiology_studies
/
Risk_factors_studies
Límite:
Humans
Idioma:
Ko
Revista:
Korean Journal of Medicine
Año:
2018
Tipo del documento:
Article